Exclusive Online Content
Choosing the Best Drug Stability Solution for a Parental Product
The development of an injectable drug product always comes with the question of the best approach to retaining the product’s stability. We asked Dr. David Brett, Product and Service Manager at Vetter, what must be considered to deal with the….
Checkpoint Therapeutics Announces FDA Filing Acceptance of BLA for Cosibelimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
Checkpoint Therapeutics, Inc. recently announced the US FDA has accepted for filing the Biologics License Application (BLA) for cosibelimab, Checkpoint’s investigational anti-PD-L1 antibody….
SiSaf & the University of Leipzig Partner to Develop Bio-Courier Targeted miRNA for the Treatment of Pancreatic Cancer
SiSaf Ltd recently announced its collaboration with the University of Leipzig, Germany, to develop Bio-Courier targeted micro interfering RNAs (miRNA) for the treatment of….
Incannex Commences Phase 2 Clinical Trial Assessing IHL-675A for use in Treatment of Pain & Function in Rheumatoid Arthritis
Incannex Healthcare Limited recently announced it has commenced a Phase 2 clinical trial to assess the safety and efficacy of its proprietary anti-inflammatory combination drug….
EyePoint & Rallybio Announce Research Collaboration
Rallybio Corporation and EyePoint Pharmaceuticals, Inc recently announced a research collaboration. The partnership will evaluate sustained delivery of Rallybio’s inhibitor of complement component….
PDS Biotech Completes Successful Meeting With FDA for Triple Combination of PDS0101, PDS0301 & a Commercial Immune Checkpoint Inhibitor
Received guidance on registrational path for combination in recurrent/metastatic, immune checkpoint inhibitor refractory head and neck cancer….
Ocean Biomedical Celebrates Discovery of Bispecific Antibodies & Immune Checkpoint Inhibitors That Kill Glioblastoma Cells & Melanoma Cells & Block the Metastasis of Malignant Melanoma Cells to the Lung by Over 90%
Ocean Biomedical, Inc. celebrates the discovery of bispecific antibodies that target Chitinase 3-like-1 and immune checkpoint inhibitors, killing glioblastoma cells and melanoma cells, and blocking the metastasis of malignant….
Cue Biopharma Enters Strategic Collaboration & Option Agreement With Ono Pharmaceutical
Cue Biopharma, Inc. recently announced a collaboration and option agreement with Ono Pharmaceutical Co., Ltd. for CUE-401, a bispecific protein designed to induce and expand regulatory….
Ajinomoto Bio-Pharma Services Successfully Develops Highly Functional Ancestral RNA Ligase
Ajinomoto Bio-Pharma Services, a leading provider of biopharmaceutical contract development and manufacturing services, recently announced the development of a new enzyme for double strand oligonucleotide formation with high….
Processa Pharmaceuticals Announces Prioritization on Development of Next-Generation Chemotherapies
Processa Pharmaceuticals, Inc. reiterates the strategic prioritization of its pipeline of proprietary oncology drugs, defined as Next-Generation Chemotherapies (NGCs). Previous studies with these….
EXCLUSIVE ONLINE CONTENT
Bespak & H&T Presspart Enter Collaboration Agreement to Advance Transition to Low GWP Propellants in pMDIs
Partnership will provide GMP filling capabilities and development support for clinical trial programs with low GWP propellants….
PCI Pharma Services Begins Installation of Sterile Fill-Finish & Lyophilization Line as Part of $100-M New Facility Expansion
PCI Pharma Services has begun installation of key equipment for its newest sterile fill-finish facility on the company’s Bedford, NH campus. Twin lyophilizers and a state-of-the-art large-scale isolator….
Medigene AG Expands Patent Portfolio With Patent Grant for its Targeted T Cell Receptor
Medigene AG recently announced it has been issued a patent by the European Patent Office protecting its T cell receptor (TCR) targeting NY-ESO-1….
Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles With siRNA Targeting p65 Protein in Treatment of Cancer & Inflammation
Altamira Therapeutics Ltd. recently announced it has filed a provisional patent application with the United States Patent Office (USPTO) which covers nanoparticles comprising the….
Adare Expands Global High Potency Handling & Packaging Capabilities
Adare Pharma Solutions, a global technology-driven CDMO specializing in oral dosage forms, recently announced expansions of its high potency handling capabilities in the….